Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study

Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) patients may be improved by a single-agent tyrosine kinase inhibitor (TKI) (i.e., quizartinib or gilteritinib). In the current study, we retrospectively investigated the characteris...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Dumas, Pierre-Yves, Bertoli, Sarah, Bérard, Emilie, Largeaud, Laetitia, Bidet, Audrey, Delabesse, Eric, Leguay, Thibaut, Leroy, Harmony, Gadaud, Noémie, Rieu, Jean Baptiste, Vial, Jean-Philippe, Vergez, François, Lechevalier, Nicolas, Luquet, Isabelle, Klein, Emilie, Sarry, Audrey, de Grande, Anne-Charlotte, Pigneux, Arnaud, Récher, Christian
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465142/
https://ncbi.nlm.nih.gov/pubmed/32722211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082044
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars